Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fight For Lipitor: FDA Calls For Dismissal Of Mylan's Plea On Ranbaxy's AIP

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The U.S. Food and Drug Administration has filed for dismissal of Mylan's March 18 motion that sought a declaratory judgement to enforce provisions of the Application Integrity Policy against Ranbaxy, calling for an immediate denial of the ANDA for Pfizer's leading cholesterol-lowering agent Lipitor (atorvastatin) to the Indian company
Advertisement

Related Content

Lipitor Generics: Judge Questions Mylan's Right To Sue Over Ranbaxy Marketing Exclusivity
Lipitor Generics: Judge Questions Mylan's Right To Sue Over Ranbaxy Marketing Exclusivity
Mylan Sues FDA Alleging Inaction And Failure To Share Clarity On Ranbaxy's Atorvastatin Filings
The Last Days Of Lipitor: Morass Of Regulatory, Legal Issues Could Mean Few Early Generics
U.S. FDA Nails Ranbaxy On Charges Of Falsifying Data; Halts All Application Reviews From Paonta Sahib Plant
U.S. FDA Nails Ranbaxy On Charges Of Falsifying Data; Halts All Application Reviews From Paonta Sahib Plant
Advertisement
UsernamePublicRestriction

Register

SC077853

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel